Roivant Sciences Ltd. (ROIV)
Free
No email, no account, no signup.
Pulling latest news for Roivant Sciences Ltd.…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report –
Order analysis – $4.99 $1.25
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Biopharmaceutical development and commercialization
Market Cap
$20.3B
Market sentiment
Sentiment has improved following the earnings update and Moderna settlement, with better funding visibility and several nearer-term data catalysts; concerns remain around burn rate and potential dilution via shelf registration.
Why BUY ?
The combination of improved liquidity outlook via the Moderna payment, clearer pipeline timelines, and reprioritization from batoclimab to IMVT-1402 improves the risk/reward into 2H 2026 readouts. Upgrading to ADD with moderate confidence given valuation already prices in some positives and clinical/commercial execution risk remains.
- ADD in tranches ahead of the July payment and 2H 2026 readouts; keep position sizing disciplined due to binary clinical outcomes and monitor any signals of financing/dilution.
We're already tracking Roivant Sciences Ltd. — here are the latest events we've registered
Recent News
- Roivant reported Q4/FY2026 on May 20, 2026, including a large one-time profit tied to the Moderna patent settlement; the company expects a $950M cash payment in July 2026 (additional amounts are contingent on litigation outcomes). Clinically, the batoclimab program was discontinued across all indications with focus shifting to IMVT-1402 (positive D2T RA data). Brepocitinib received Breakthrough Therapy Designation for cutaneous sarcoidosis, and management guided to multiple topline readouts in 2H 2026 plus a planned dermatomyositis launch in late September 2026.
Want to know how this news affects Roivant Sciences Ltd.? Order the analysis.
Order analysis – Catalysts
1 Jul 2026 — Moderna payment ($950M) expected in July 2026
Dilution Risk
Assessment: Medium
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Sources: news, filings, market data, and investor forums
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Roivant Sciences Ltd. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.